PUPH Researchers find Haplo-HSCT Superior to Chemotherapy for Int-risk AML CR1
May 09, 2019
Peking University, May 9, 2019: Researchers at Peking University People’s Hospital found strong clinical evidence for treatment choice in intermediate-risk acute myelogenous leukemia (AML) in first complete remission. The study, titled “Haplo-HSCT Is Superior to Chemotherapy for Int-risk AML CR1”, was conducted by a group led by Professor Huang Xiaojun, and appeared in the March issue of Clinical Cancer Research, journal of the American Association for Cancer Research (AACR).
Previously, this same group had developed the so-called Beijing Protocol of myeloablative HLA haploidentical hematopoietic stem cell transplantation (haplo-HSCT) following pretransplant anti-thymocyte globulin (ATG) and granulocyte colony-stimulating factor (G-CSF) stimulated grafts (ATG+G-CSF), as an alternative to conventional HSCT from HLA-matched sibling donors (MSD). The recently published article showed that the haplo-HSCT group had higher 3-year leukemia-free survival (LFS) and overall survival (OS) than the chemotherapy group, and that postremission treatment (haplo-HSCT vs. chemotherapy) was an independent risk factor affecting the LFS, OS and cumulative incidence of relapse.
Written by: Fan Xiaofei
Edited by: Huang Weijian
Source: Peking University People’s Hospital (Chinese)
